All In Biotech

Drug Trial Radar · NCT06393803

Phase 1 Study of KH607 Tablets

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses of KH607 Tablets in Chinese Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: May 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

88

Planned (sponsor's estimate)

Start

Oct 21, 2023

Primary completion

Oct 30, 2024

Study completion Oct 30, 2024

Sponsor

Sponsor type
Industry
First posted
May 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study was a single-center, randomized, double-blind, placebo-controlled study divided into a Single Ascending Dose (SAD) stage and a Multiple Ascending Dose (MAD) stage. The primary objective was to evaluate the safety and tolerability of KH607 tablets in Chinese healthy volunteers.

Conditions

  • Healthy

Interventions

  • 2mg KH607 tabletsDrug

    Subject receive KH607 tablets or placebo orally single dose.

  • 5mg KH607 tabletsDrug

    Subject receive KH607 tablets or placebo orally single dose.

  • 10mg KH607 tabletsDrug

    Subject receive KH607 tablets or placebo orally single dose or multiple doses.

  • 20mg KH607 tabletsDrug

    Subject receive KH607 tablets or placebo orally single dose or multiple doses.

  • 30mg KH607 tabletsDrug

    Subject receive KH607 tablets or placebo orally single dose or multiple doses.

  • 40mg KH607 tabletsDrug

    Subject receive KH607 tablets or placebo orally single dose.

  • 50mg KH607 tabletsDrug

    Subject receive KH607 tablets or placebo orally single dose.

  • 60mg KH607 tabletsDrug

    Subject receive KH607 tablets or placebo orally single dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 12-lead ECGsTime frame: Screening up to Part 1 Days, Part 2 Day14.
  2. Physical ExaminationTime frame: Screening up to Part 1 Days, Part 2 Day14.
  3. 12-lead ECGsTime frame: Screening up to Part 2 Day14.
  4. Stanford Sleepiness ScaleTime frame: Screening up to Part 1 Day3,Part 2 Day14.
  5. Modified Observer's Assessment of Alertness/Sedation scaleTime frame: Screening up to Part 1 Day3,Part 2 Day14.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anding Hospital Affiliated to Capital Medical University

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.